Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis - Top-Institutions - MDSpire

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis

  • By

  • María Velasco-de-Andrés

  • Pedro Puerta-Alcalde

  • Jiri Eitler

  • Lydia Krutz

  • Mariana Chumbita

  • Marta Español-Rego

  • Cristina Català

  • Laura Carrillo-Serradell

  • Violeta Planells-Romeo

  • Lucía Aragón-Serrano

  • Andrea Vergara

  • Amanda Isabel Pérez-Valencia

  • Patricia Monzó-Gallo

  • Antonio Gallardo-Pizarro

  • María Teresa Cibeira

  • Alexandru Vlagea

  • José Luis Caro

  • Eduard Palou

  • María Suárez-Lledó

  • Alex Soriano

  • Gonzalo Calvo

  • Álvaro Urbano-Ispizua

  • Torsten Tonn

  • Carolina Garcia-Vidal

  • Francisco Lozano

  • May 8, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Terry Fox Laboratory, BC Cancer Agency
    Terry Fox Laboratory, BC Cancer Agency

    Vancouver, BC

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Goethe University Frankfurt
    Goethe University Frankfurt

    Frankfurt, Hesse

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    First Affiliated Hospital of Soochow University
    First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Hannover Medical School
    Hannover Medical School

    Hannover, Lower Saxony

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis

  • by María Velasco-de-Andrés, Pedro Puerta-Alcalde, Jiri Eitler, Lydia Krutz, Mariana Chumbita, Marta Español-Rego, Cristina Català, Laura Carrillo-Serradell, Violeta Planells-Romeo, Lucía Aragón-Serrano, Andrea Vergara, Amanda Isabel Pérez-Valencia, Patricia Monzó-Gallo, Antonio Gallardo-Pizarro, María Teresa Cibeira, Alexandru Vlagea, José Luis Caro, Eduard Palou, María Suárez-Lledó, Alex Soriano, Gonzalo Calvo, Álvaro Urbano-Ispizua, Torsten Tonn, Carolina Garcia-Vidal, Francisco Lozano

  • May 8, 2026

Related Content

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.

Analysis of infection characteristics and clinical predictive indicators of different bacterial diabetic foot in Yunnan area